8 hours ago
Zai Lab (ZLAB) Delivers Positive ZL-1503 Trial Results in Treatment of Atopic Dermatitis
Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive trial results from a preclinical study of ZL-1503, a promising IL-13/IL-31R bispecific antibody.
Chemists in a laboratory studying beakers of liquid as they work to develop biopharmaceuticals for chronic inflammation and asthma.
In the study, the IL-13/IL-31R bispecific antibody demonstrated the ability to suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The trial results underscore the potential of ZL-1503 to act as a novel treatment option for moderate-to-severe AD.
Some key findings include a single dose of ZL-1503 (10 mg/kg, iv) completely inhibiting IL-13-mediated pSTAT6 and IL-31-induced scratching for at least 76 days. In addition, two out of three subjects exhibited prolonged IL-13-mediated pSTAT6 inhibition over 118 days. Following the positive preclinical study, Zai Lab plans to file an IND for ZL-1503 for moderate-to-severe atopic dermatitis by the end of the year.
Zai Lab Limited (NASDAQ:ZLAB) is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease.
While we acknowledge the potential of ZLAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On.
Disclosure: None.
